Medivir AB
MVIR.ST
Get informed when a big investor buys or sells
+ FollowMarket Cap$932.31M
Close$
Share Statistics
| Market cap | $932.31 Million |
|---|---|
| Enterprise Value | $949.49 Million |
| Dividend Yield | $- (NaN%) |
| Earnings per Share | $- |
| Beta | 0.72 |
| Outstanding Shares | - |
Return
| Return on Equity | -45.99% |
|---|---|
| Return on Assets | -37.86% |
| Return on Invested Capital | -33.32% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 215.4 |
| Enterprise Value to EBIT | -13.82 |
| Enterprise Value to Net Income | -11 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.12 |
Revenue Sources
No data
Insider Trades
Next Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.09
Average shareholder expectationRevenue Estimate
$2.31 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Medivir AB (publ)
10 employees
CEO: Jens Lindberg Established in 1987 and headquartered in Huddinge, Sweden, Medivir AB (publ) is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products. Its primary therapeutic area is oncology,...